RESEARCH TRIANGLE PARK, N.C., May 7, 2026
Opus Genetics announced new clinical and preclinical data presentations at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, highlighting significant progress across its inherited retinal disease (IRD) gene therapy pipeline. The company presented encouraging six-month clinical findings from its OPGx-LCA5 pediatric study, early clinical evidence supporting OPGx-BEST1, and new preclinical data advancing its RHO mutation-independent retinal therapy platform. Collectively, the presentations reinforce Opus Genetics’ strategy of developing one-time gene therapies designed to restore vision and prevent blindness in patients affected by severe genetic retinal disorders. The data also demonstrated continued advancements in manufacturing, potency assays, and scalable development processes intended to support future regulatory pathways and commercial readiness for multiple investigational retinal therapies.
OPGx-LCA5 Demonstrates Restoration of Cone-Mediated Vision in Pediatric Patients
The company’s featured oral presentation focused on six-month clinical data from the ongoing Phase 1/2/3 trial evaluating OPGx-LCA5 in pediatric patients with Leber congenital amaurosis type 5 (LCA5), a rare inherited retinal degeneration associated with severe early-onset blindness. According to the data presented by principal investigator Tomas S. Aleman, M.D., pediatric patients receiving a single subretinal injection of OPGx-LCA5 demonstrated substantial restoration of cone-mediated daytime vision despite advanced baseline disease severity and significantly impaired visual function prior to treatment.
Opus Genetics reported that treated patients achieved more than 30-fold improvements in cone sensitivity, with some sensitivity measurements reaching ranges considered normal. Additional findings included measurable improvements in visual acuity compared with untreated control eyes, objective efficacy confirmation through dark-adapted pupillary light response testing, and durable improvements in orientation and mobility assessments. The therapy was reported to be well tolerated, with no dose-limiting toxicities observed and adverse events described as mild, expected, and resolved. Patient-reported outcomes also suggested meaningful improvements in daily functional vision activities following treatment.
Company executives stated that the findings provide further evidence supporting the possibility of rescuing viable cone photoreceptors even in severe pediatric retinal disease, potentially expanding the therapeutic window for inherited retinal degeneration gene therapies. The results also build upon previously reported adult data from the same program, strengthening confidence in the broader clinical potential of OPGx-LCA5.
Advertisement
Early BEST1 Clinical Data Support Expansion Into Broader IRD Populations
Additional ARVO presentations highlighted preliminary clinical findings from the company’s OPGx-BEST1 Phase 1b/2a study targeting patients with retinal degeneration associated with BEST1 mutations, including autosomal recessive bestrophinopathy (ARB) and Best vitelliform macular dystrophy (BVMD). Early three-month clinical data from the first treated adult participant demonstrated encouraging improvements in both visual function and retinal structure.
According to Opus Genetics, the therapy was well tolerated with no ocular inflammation or treatment-related adverse events reported during the observation period. The treated eye demonstrated up to a 12-letter improvement in visual acuity, alongside an approximately 23% reduction in central retinal thickness, indicating potential structural retinal recovery. The patient also reported subjective improvements in progressive vision dimming symptoms. The company believes these findings support broader development opportunities for BEST1-targeted gene augmentation therapies across larger inherited retinal disease populations. Enrollment for Cohort 1 of the ongoing clinical study has been completed, with topline data expected later in 2026.
Mutation-Independent RHO Platform Advances Toward Clinical Translation
Opus Genetics also presented multiple preclinical studies involving its RHO mutation-independent retinal degeneration programs, which are designed to address genetically diverse forms of autosomal dominant retinitis pigmentosa using a single therapeutic platform. In canine and swine disease models, investigational therapies demonstrated durable retinal preservation, restoration of rod-mediated visual responses, maintenance of cone function, and preservation of retinal structure over extended observation periods.
The company reported that its mutation-independent adeno-associated virus (AAV) knockdown-and-replacement strategy successfully preserved photoreceptor morphology and retinal thickness while identifying dose ranges suitable for future clinical translation. Researchers also observed potential interocular vector transfer, providing new insight into systemic distribution characteristics of retinal gene therapies. These programs are intended to overcome limitations associated with mutation-specific therapies by offering broader applicability across heterogeneous retinal disease populations.
In parallel, Opus Genetics showcased advancements in manufacturing and potency assay development for OPGx-BEST1, including validated gene expression assays, protein quantification methods, and functional testing platforms designed to support scalable production consistency and regulatory readiness as programs progress toward later-stage development.
Source: Opus Genetics press release
